Labopharm Reports Results for Third Quarter F...(33 Loss on sale of property p...),Health
Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2009
Date:11/6/2009
33 Loss on sale of property, plant and equipment 65 - 65 - Impairment loss on long-term investment - 400 - 1,091 Non-cash financial expenses 206 101 496 288 Unrealized foreign exchange loss (gain) (1,177) 647 (2,012) 386 Stock-based compensation 136 410 1,339 1,981 ------------------------------------------------------------------------- (7,196) (3,952) (18,416) (20,758) Net change in non-cash items 1,502 (6,623) (834) (5,906) ------------------------------------------------------------------------- (5,694) (10,575) (19,250) (26,664) ------------------------------------------------------------------------- INVESTING ACTIVITIES Acquisition of marketable securities - (16,962) (8,466) (40,515) Proceeds from maturities of marketable securities 595 - 23,605 - Proceeds from disposals of marketable securities 3,400 11,200 9,420 67,019 Acquisition of restricted long-term investment - - - (45) Acquisition of property, plant and equipment (251) (196) (319) (1,344) Acquisition of intangible assets (4) (57) (57) (96) ------------------------------------------------------------------------- 3,740 (6,015) 24,183 25,019 ------------------------------------------------------------------------- FINANCING ACTIVITIES Repaym
'/>"/>
| SOURCE Labopharm Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
2. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
3. Labopharm submits response to FDA for novel antidepressant
4. Labopharm Reports Results for Second Quarter Fiscal 2009
5. Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
6. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
7. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
8. Labopharm amends debt facility agreement with Hercules
9. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
10. Labopharm Reports Results for First Quarter Fiscal 2009
11. Labopharm announces details for first quarter results conference call and annual meeting
Post Your Comments:
(Date:11/27/2009)..., , KIBBUTZ SHAMIR, Israel, Nov. 27 /PRNewsw...sdaq: SHMR ) ( "Shamir" ), a leading provider of ...ic lens market, announced today that its board of ...an aggregate amount of US$ 10 million (approximate...9 representative rate of exchange), or approximate...
(Date:11/27/2009)...oaring rates to bring unprecedented medical, econo...Nov. 27 (HealthDay News) -- The number of people w...ouble over the next 25 years, a new study predicts... 44.1 million people with the disease, up from 23....of treating people with diabetes will triple, the ...
(Date:11/27/2009)... Multi-purpose bilingual c...Designed for use by the business community to educ...ty of subjects from Safety issues to Dinosuars to ... Saint Louis, MO (PRWEB) November 27, 20...electronics or toys to keep them busy any hour of ...
(Date:11/26/2009)..., , NEW YORK, Nov. 27 With ...han ever to employ good practices to control the s...eed to be proactive not only to keep ourselves hea...ick," said Eileen Finerty, RN, MS, CIC (certified ...ion control and occupational health at Hospital fo...
(Date:11/26/2009)... The copper sequestering drug tetrathiomolybdate (...he treatment of Wilson disease, a disease caused b...ncers. That much is known. Very little, however, i...level. , A new study led by Northwestern Univers...e: the three-dimensional structure of TM bound to ...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3[0] Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend[0] Diabetes Cases Expected to Double in 25 Years[1] Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books [1] Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use[1] Research sheds light on workings of anti-cancer drug
... Products in our Molluscum Line,in the First Quart...er,Medical Technologies, Inc. (Pink Sheets: RBRM),... for diabetic peripheral neuropathy, Molluscum,Con...GO ), "We are projecting that sales will have do...
... leave the,hospital after prostate surgery, they a... than not, a spouse is called on to be the caregiv...rmation and confidence,necessary to provide all th...chigan, has developed,a program that helps couples...
... The largest study to examine the effect of depre...ficantly worsens a patients adherence to highly ac... but that effective antidepressant medication can ...ine issue of the Journal of Acquired Immune Defici...
... School Breakfast to Enable More ...ec. 21 Tami Cline, Executive,Director of the "got...ment,today following the recent release of the Flo...children from elementary through high school is a ...
...ea Health,Council,s (GDAHC) Save Lives Save Dollar...can Diabetes Association, sanofi-aventis, and the ...t program to help people with,diabetes better mana...ME) training that will help employees with,diabete...
...Online Nurse Community, SAN DIEGO, Dec. 21 Web s...als to connect with their peers are growing in,pop...e rising to the top,designed exclusively for nursi... site for collaboration, sharing,of ideas and reco...
Other Medicine News:Health News:ReBuilder Medical Technologies, Inc. 4th Quarter Sales Increase 100% Exceeding Projections 2Health News:Helping Couples Fight Prostate Cancer, This Week on Your Cancer Today(TM) 2Health News:'got breakfast?'(TM) Foundation Issues Statement on Recently Released Florida State Plan of Action from the Governor's Council on Physical Fitness 2Health News:'got breakfast?'(TM) Foundation Issues Statement on Recently Released Florida State Plan of Action from the Governor's Council on Physical Fitness 3Health News:GDAHC Save Lives Save Dollars Initiative Launches Pilot Program for Diabetes Care Management 2Health News:GDAHC Save Lives Save Dollars Initiative Launches Pilot Program for Diabetes Care Management 3Health News:Professional Networking Web Site, NurseConnect.com Launches Innovative Features 2ReBuilder Medical Technologies, Inc. 4th Quarter Sales Increase 100% Exceeding ProjectionsHelping Couples Fight Prostate Cancer, This Week on Your Cancer Today(TM)Kaiser Permanente -- Group Health study shows depression worsens HIV treatment'got breakfast?'(TM) Foundation Issues Statement on Recently Released Florida State Plan of Action from the Governor's Council on Physical FitnessGDAHC Save Lives Save Dollars Initiative Launches Pilot Program for Diabetes Care ManagementProfessional Networking Web Site, NurseConnect.com Launches Innovative Features
(Date:11/25/2009).... 25 /PRNewswire-Asia-FirstCall/ -- China Sky One,...pany") (Nasdaq: CSKI ), a,leading fully integrate...over-the-counter drugs in the People,s Republic of...ecently passed the Chinese National Institute for,...cts ("ICPBP") examination,for two of its new produ...
(Date:11/25/2009)...Newswire/ -- Reportlinker.com announces that a new...gue: ,, Mammography Equipment - A Global Mark...m/p0164330/Mammography-Equipment---A-Global-Market...t cancer in industrialized as well as developing n... the mammography market. Globally, escalating awar...
(Date:11/25/2009)...v. 25 Swissray International, Inc....phy ( ddR ) systems, announced today that its oper...tor with a long term view towards growing Swissray... all assets and intellectual property, as well as ... and growth Swissray is now poised to move to the ...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8Swissray International Announces New Ownership 2AMD LASERS Announces New Partnership with Dr Larry Rosenthal and Aesthetic Advantage 6460 1AMD LASERS Announces New Partnership with Dr Larry Rosenthal and Aesthetic Advantage 6460 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 1Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 1Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 5Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 6Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 7Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 8Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 9Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 10...RNewswire-FirstCall/ -- Sunesis Pharmaceuticals, I...data from ongoing clinical,studies of SNS-595 and ...ology Association (EHA) being held June 7-10, 2007...updated interim data from the,company,s Phase 1 cl...l as clinical data from an ongoing study of SNS-03...
... -- Forest,Laboratories, Inc. and PAION AG today a...se In Acute Ischemic Stroke) study with the,compou...to,investigate the improvement of clinical outcome...th Desmoteplase within 3 to 9 hours,after onset of...ry,efficacy endpoint (difference between active tr...
Other Medicine Technology:Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 2Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 3Topline Results of Phase III Study in Acute Ischemic Stroke,(Dias-2) Do Not Demonstrate Difference Between Desmoteplase and,Placebo 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |